The George Institute for Global Health, Sydney, Australia.
Intensive Care Med. 2013 Apr;39(4):558-68. doi: 10.1007/s00134-013-2840-0. Epub 2013 Feb 14.
To determine whether fluid resuscitation of acutely ill adults with 6 % hydroxyethyl starch (6 % HES 130) with a molecular weight of 130 kD and a molar substitution ratio of approximately 0.4 (6 % HES 130) compared with other resuscitation fluids results in a difference in the relative risk of death or treatment with renal replacement therapy (RRT).
Systematic review and meta-analysis of randomized controlled trials comparing intravascular fluids for resuscitation of hospitalised adults that reported mortality or treatment with RRT. The risk of bias was assessed independently by two reviewers and meta-analysis was performed using random effects.
Thirty-five trials enrolling 10,391 participants were included. The three largest trials had the lowest risk of bias, were published (or completed) in 2012, and together enrolled 77 % of all participants. Death occurred in 928 of 4,691 patients (19.8 %) in the 6 % HES 130 group versus 871 of 4,720 (18.5 %) in the control fluid groups relative risk (RR) in the 6 % HES 130 group 1.08, 95 % confidence interval (CI) 1.00 to 1.17, I (2) = 0 %). Treatment with RRT occurred in 378 of 4,236 patients (8.9 %) in the 6 % HES 130 group versus 306 of 4,260 (7.2 %) in the control fluid group (RR in the 6 % HES 130 group 1.25, 95 % CI 1.08 to 1.44, I (2) = 0 %).
The quality and quantity of data evaluating 6 % hydroxyethyl starch (130/0.4 and 130/0.42) as a resuscitation fluid has increased in the last 12 months. Patients randomly assigned to resuscitation with 6 %HES 130 are at significantly increased risk of being treated with RRT.
比较急性病患者接受分子量为 130kD、摩尔取代度约为 0.4 的 6%羟乙基淀粉(6%HES130)和其他复苏液的液体复苏治疗后,其死亡率或肾脏替代治疗(RRT)的相对风险是否存在差异。
系统评价和荟萃分析比较了用于住院成人复苏的血管内液体的随机对照试验,这些试验报告了死亡率或 RRT 的治疗情况。两名评审员独立评估偏倚风险,并使用随机效应进行荟萃分析。
纳入了 35 项试验,共 10391 名参与者。其中三项最大的试验具有最低的偏倚风险,发表于(或完成于)2012 年,共纳入了所有参与者的 77%。在 6%HES130 组中,有 928 名(19.8%)/4691 名患者死亡,而在对照组中,有 871 名(18.5%)/4720 名患者死亡。6%HES130 组的相对风险(RR)为 1.08,95%置信区间(CI)为 1.00 至 1.17,I²=0%)。在 6%HES130 组中,有 378 名(8.9%)/4236 名患者接受了 RRT 治疗,而在对照组中,有 306 名(7.2%)/4260 名患者接受了 RRT 治疗。6%HES130 组的 RR 为 1.25,95%CI 为 1.08 至 1.44,I²=0%)。
在过去的 12 个月中,评估 6%羟乙基淀粉(130/0.4 和 130/0.42)作为复苏液的质量和数量有所增加。随机分配到 6%HES130 复苏的患者接受 RRT 治疗的风险显著增加。